Myocardial Reinfarction Prevention — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for myocardial reinfarction prevention. 24 active patents protecting 2 drugs from 2+ originators. First major cliff: 2026. Daily refresh.

2
Approved drugs
24
Active US patents
67/100
Avg vulnerability
$15.5B
Annual revenue covered

Originators in Myocardial Reinfarction Prevention

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bristol-Myers Squibb 16 patents AstraZeneca 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating myocardial reinfarction prevention. Each bar = one year. Y-axis scaled to peak year (6 patents).

4
26
4
27
4
30
6
31
4
36
1
40
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Eliquis
apixaban
 Bristol-Myers Squibb 16 72 $14.4B 2026-11-21
Brilinta
ticagrelor
 AstraZeneca 8 61 $1.1B 2030-04-17

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
6967208 Eliquis method of use 93 2026-11-21
6967208 Eliquis method of use 93 2026-11-21
6967208 Eliquis method of use 85 2026-11-21
6967208 Eliquis method of use 85 2026-11-21
6967208 Eliquis other 75 2027-05-21
6967208 Eliquis other 75 2027-05-21
6967208 Eliquis other 75 2027-05-21
6967208 Eliquis other 75 2027-05-21
11896586 Eliquis method of use 75 2040-11-22
8425934 Brilinta other 68 2030-10-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9326945 Eliquis formulation 48 2031-02-24
9326945 Eliquis formulation 48 2031-02-24
8425934 Brilinta formulation 48 2030-04-17
8425934 Brilinta formulation 53 2030-04-17
9326945 Eliquis formulation 61 2031-02-24
11896586 Eliquis other 62 2041-05-22
10300065 Brilinta other 62 2036-07-27
10300065 Brilinta other 62 2036-07-27
10300065 Brilinta method of use 62 2036-01-27
10300065 Brilinta method of use 62 2036-01-27

Related